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Abstract
Objective: To evaluate the use of two phototherapy guidelines for the treatment of hyperbilirubinemia in newborn
babies weighing less than 2,000 g.
Methods: Eighty-one newborn infants with birth weight less than 2,000 g were studied. They were divided in two
groups: the early group, which started phototherapy 12 hours after birth, undergoing treatment for at least 96 hours;
and the late group, which received phototherapy whenever the transcutaneous bilirubin reached 8 mg/dl and
phototherapy suspended when bilirrubin levels fell to 5 mg/dl. The following factors were analyzed: maintenance of
transcutaneous bilirubin levels below 10 mg/dl, mean value of daily transcutaneous bilirubin, the highest transcutaneous
bilirubin value and the period it first occurred, and duration of treatment.
Results: In the early group, 20% of all patients showed transcutaneous bilirubin level higher than 10 mg/dl compared
to 60% of patients in the late group. The highest daily mean rate of transcutaneous bilirubin in the early group was 6.6
mg/dl, which happened on the 7th day. In the late group, it was 8.6 mg/dl on the 2nd day after birth. The median duration
of phototherapy treatment used in the early group was 96 hours (minimum of 96 and maximum of 156 hours) and in the
late group, 51 hours (minimum of zero and maximum of 120 hours). None of the babies needed changes in the treatment
(double phototherapy or exchange transfusion).
Conclusion: The use of early phototherapy treatment for babies weighing less than 2,000 g is safer when compared
to the late group, considering satisfactory the maintenance of transcutaneous bilirubin levels below 10 mg/dl.
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Introduction
Neonatal jaundice is characterized by yellow coloration
of the skin in newborns due to bilirubin levels greater than
5 to 7 mg/dl.1,2 Two thirds of newborns develop jaundice
in their first week of life. A wide series of situations (e.g.:
prematurity) may cause bilirubin levels to increase
excessively, and bilirubin then leaks into several tissues,
including the central nervous system. The large amount
of bilirubin for long periods may permanently damage
structures such as the globus pallidus, subthalamic nuclei,
hippocampus, and oculomotor nucleus, among others,
resulting in the so-called kernicterus.3
Premature infants often are subject to this disease
due to factors such as low albumin level;4 a less stable
b i l i rub in-a lbumin b ind ing;5 reduced hepat ic
glucuronidation;6 immature blood-brain barrier;7
hyperbilirubinemia, as well as associated diseases such
as asphyxia, infections, hypercarbia and hyperosmolarity,
which increase the permeability of the blood-brain
barrier,7,8 and the metabolization of bilirubin by the
central nervous system via oxidation is underdeveloped in
premature infants.9
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Controversy still exists among experts over the high
bilirubin levels that could cause injury to premature babies.
There have been reports of kernicterus at very low levels
among newborns. It is advisable to prevent the exposure of
infants to bilirubin levels greater than the physiological
ones.10. Levels below 10 mg/dl are seemingly safe, although
it is commonly known that other factors are implicated in the
development of kernicterus in preterm babies.
Phototherapy has been the treatment of choice in the
last 30 years11 because of its efficiency in the management
of preterm babies and also because it has no severe side
effects. Two types of treatment have been used:
prophylactic, which should be preferably called early
treatment, since it does not prevent jaundice, which
develops within the first 12 to 24 hours of life and usually
lasts for  96 hours, and therapeutic, or late treatment,
implemented according to a certain bilirubin level until
lower values are obtained. Both treatments have their
advantages and disadvantages, and because of that, no
common agreement has been reached on which treatment
should be used.
The determination of bilirubin levels has improved
substantially, having become miniaturized, simpler, less
invasive and cheaper.
By applying new and noninvasive methods for bilirubin
measurement and very efficient phototherapy equipment,
the present study aims at comparing the early and late
treatments of jaundiced newborns weighing less than
2,000 g, defining which treatment is more satisfactory,
allowing lower exposure to high bilirubin levels, lower
costs and more comfort to patients.
Methods
We carried out a controlled, clinical randomized study
at the Center for Womens Health (CAISM) and Hospital
Estadual de Sumaré (HES), public tertiary institutions
affiliated with Universidade Estadual de Campinas-
UNICAMP.  Serum bilirubin concentration was assessed in
81 neonates, born consecutively between July 31st and
November 2nd, 2001, with birthweight less than 2,000 g.
The patients were placed in two groups (randomly drawn
out) within the first 12 hours of life. The exclusion criteria
included any evidence of hemolysis, characterized by
hemolytic disease due to Rh incompatibility or rare antigen,
with positive indirect Coombs test in maternal serum or
positive direct Coombs test in the newborn;12 hemolytic
disease due to ABO incompatibility with an indirect bilirubin
level greater than 8 mg/dl in the first 24 hours of life and
reticulocytosis according to the criteria established by
Blanchette & Zipursky13; G6PD deficiency; malformations;
intestinal obstruction; cholestasis; congenital infections;
maternal or neonatal use of phenobarbital; transcutaneous
bilirubin (TB) level greater than 15 mg/dl at any age, due
to the necessity to change the treatment (double
phototherapy or exchange transfusion). Eleven patients
were excluded: ten of them died and one had a positive
direct Coombs test.
In the early-treatment group, newborns were submitted
to phototherapy 12 hours after birth, regardless of their
bilirubin concentration, up to 96 hours of life. In the late-
treatment group, phototherapy was started only when
bilirubin concentration reached 8 mg/dl and was
discontinued when it fell to 5 mg/dl or less. The first
measurement of bilirubin levels was performed before
phototherapy in both groups, and every day during seven
days, using the Bilicheck bilirubin analyzer (SpectRx Inc.-
Norcross, Georgia, USA), in the frontal region, which was
covered with aluminum foil to protect the patient from the
phototherapy. Bilical calibration tips were used for each
measurement, according to the manufacturer s
instructions.
To control the measurements performed by Bilicheck,
capillary blood was regularly collected and direct
spectrophotometry was made using the Leica Unistat
bilirubinometer. A bilirubin calibration standard containing
25.9±0.98 mg/dl was used, as recommended by the Joint
Committee Report.14,15 The bilirubinometer was calibrated
every day with the default optical standards, and after
that, it was calibrated by this calibration standard in
triplicate, so that its reliability could be checked.
We used eight FANEM Mod 007 devices equipped with
seven Philips TL20W/52 fluorescent lamps (special blue), at
the wavelength of  400 to 540 nm and with a peak output of
450 nm. The equipment was placed 1 cm far away from the
overhead heater unit, and spectral irradiance was measured
using a custom-made radiometer (International Light - IL
1700), calibrated according to the recommendations of the
U.S. National Institute of Standards and Technology,
containing an SED 033/tblu sensor, at the wavelength of
345 to 530 nm and with a peak output of 460 nm. Irradiance
was measured at nine different spots at the level of the
incubator mattress, for calculation of average spectral
irradiance, as recommended.16,17 Average spectral
irradiance was measured 200 hours after the use of the
lamps, with an average of 14.4 µW/cm2/nm. A 20% decrease
in average spectral irradiance was tolerated at the beginning
of phototherapy.18
The analyzed variables were: peak bi l i rubin
concentration, the mean value of daily bilirubin levels,
expressed in mg/dl; and length of phototherapy, expressed
in hours. The control variables used to check the
randomization of groups were: prematurity (gestational
age < 37 weeks), birthweight, appropriateness for
gestational age, gender, race, type of delivery, previous
child with jaundice, maternal diabetes and smoking (>3
cigarettes/day), birth trauma, polycythemia (ht > 65%),
perinatal anoxia (Apgar at 5 min < 5), sepsis, hypoglycemia
(blood sugar level < 40 mg/dl), peri-intraventricular
hemorrhage, hypoxemia (pO2 < 50 mmHg), metabolic
acidosis  (pH < 7.20), respiratory distress syndrome,
presence of fasting, type of enteral nutrition and use of
parenteral nutrition.
Seventy newborns were necessary for this study,
based on a previous calculation made by Brown.19 The
results were logged into a database using Epi-Info 6 and
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the statistical analysis was made using SAS version 8.02.
Bilirubin curves were plotted for both groups, and the
difference between groups was determined by repeated
measures ANOVA. A box-plot was constructed with
phototherapy hours for both groups, and the difference
between the groups was verified using Wilcoxons test. A
significance level of α = 0.05 was established.
The study was approved by the Research Ethics
Committee of the School of Medicine of UNICAMP, and an
informed consent form was signed by parents before the
inclusion of their children in the study.
Results
Twenty-three control variables regarding mothers and
their respective newborns were analyzed (Table 1),
revealing that both groups are apparently homogeneous.
Bilirubin levels reached or exceeded 10 mg/dl in seven
newborns of the early-treatment group (20%) and in 21
newborns of the late-treatment group (60%), p = 0.0015.
Table 1 - Distribution of newborns weighing less than 2,000 g in the early and late
groups according to the control variables
Variable Early Late
n (35) % n (35) %
Smoking mother (> 3 cigarettes a day) 5 14.3 7 20.0
Diabetic mother 0 0.0 1 2.9
Cesarean delivery 26 74.3 24 68.6
Kernicterus in previous child 3 8.6 3 8.6
Male 21 60.0 16 45.7
Caucasian 24 68.6 23 65.7
Preterm (GA < 37 weeks) 35 100.0 33 94.3
Preterm with GA < 34 weeks 27 77.1 26 74.3
Birth weight > 1,500 g 16 45.7 15 42.9
Small for gestational age 17 48.6 13 37.1
Apgar at 5 minute < 5 0 0.0 1 2.9
Birth trauma 5 14.3 5 14.3
Hypoglycemia (glycemia < 40 mg/dl) 3 8.6 0 0.0
Polycythemia (ht > 65%) 8 22.9 5 14.3
Respiratory distress syndrome 15 42.9 10 28.6
Sepsis 5 14.3 2 5.7
Peri-intraventricular hemorrhage 0 0.0 2 5.7
Metabolic acidosis (pH < 7.20) 2 5.7 4 11.4
Hypoxemia (pO2 < 50 mmHg) 5 14.3 8 22.9
Presence of fasting 3 8.6 3 8.6
Breastfeeding 7 20.0 10 28.0
Use of parenteral nutrition 25 71.4 22 62.8
Use of child formula 30 85.7 29 82.8
GA = gestational age.
The mean bilirubin levels reached by both groups were
analyzed between the first and seventh days of life, and
the curves of mean total bilirubin (TB) for both groups are
shown in Figure 1. The highest TB mean in the early-
treatment group, which occurred on the last day of the
study, was of 6.6 mg/dl. In the late-treatment group, the
highest mean (8.6 mg/dl) occurred on the second day of
life, where p < 0.01 (Table 2). In terms of absolute values,
the highest TB level was of 13 mg/dl and 14.6 mg/dl in the
early- and late-treatment groups, respectively.
The total length of phototherapy (in hours) in both
groups is shown in Figure 2, where the 25th, 50th
(median) and 75th percentiles are observed. In the early-
treatment group, the median was of 96 hours of
phototherapy, coinciding with the minimum value, whereas
the maximum value was of 156 hours. In the late-
treatment group, the median was of 51 hours, and only
one newborn did not need phototherapy since a bilirubin
level of 8 mg/dl was not reached. The maximum use of
phototherapy was of 120 hours in this group.
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Figure 2 - Evaluation of total length of phototherapy (in hours)
in both groups















Table 2 -  Daily evaluation of mean total bilirubin (and standard deviation) in the early and late groups (in mg/dl)
ANOVA * p < 0.01
1st day 2nd day 3rd day 4th day 5th day 6th day 7th day
Group* early 4.1±1.38 4.6±1.93 4.7±2.54 4.9±2.26 4.6±1.82 6.1±2.31 6.6±2.84
Group* late 5.3±1.56 8.6±2.08 7.8±2.61 5.9±2.43 5.7±2.75 5.7±2.37 6.3±2.93









































Our study confirms that early treatment considerably
reduced the number of newborns weighing less than
2,000 g, which had exceeded 10 mg/dl in the first week
of life. This difference is quite expressive in percentage
terms (p < 0.01) as it occurred in only 20% of newborns
compared to 60% of those who received late treatment,
a result that is inconsistent with previous studies.20,21
The mean bilirubin concentrations were lower in the
early-treatment group, being equal to and slightly higher
than the values found for the late-treatment group on the
sixth and seventh days of life. In the latter group, on the
second day, the mean reached values greater than those
which indicate the necessity for treatment, while in the
early-treatment group levels of 8 mg/dl were not obtained.
Again, these values differ from those found by Curtis-
Cohen et al.20 in 1985.
This discrepancy in efficiency may perhaps be explained
by the fact that in these studies, although the authors
waited for bilirubin levels to reach 5 mg/dl before starting
phototherapy, these levels occurred quite near the
beginning of early treatment, thus masking the increase
we detected on the second and third days. The use of
phototherapy equipment with efficient average spectral
irradiance16,22,23 caused the levels to be very close to
those of early-treated infants in the study carried out by
Curtis-Cohen et al.20 If we had used the same criterion for
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the late-treatment group we would not probably have
found any significant difference between the two groups
tested. When both groups were divided into subgroups
according to their weight (< 1,000 g, 1,000 to 1,500 g,
and  > 1,500 g), there was a clear difference as to the
incidence of levels greater than 10 mg/dl, although the
number of cases in each subgroup does not allow any
statistical evaluation. For instance, in the early-treatment
group, there were four patients weighing less than 1,000
g compared to eight patients with such weight in the late-
treatment group, which could clearly influence the analysis
of results if it were separately made in each weight
subgroup. There is some agreement on the fact that
preterm babies and very low weight children are at a
greater risk for bilirubin-induced brain injury. These
levels are not well-established due to the ethical
impossibility of comparison with control groups. Some
studies10,24,25 recommend maintaining the levels below
10 mg/dl whenever possible. Therefore, they indicate
exchange transfusion in newborns weighing less than
1,000-1,250 g with bilirubin levels above 10 mg/dl. This
practice is still followed by many neonatology units,
despite being economically prohibitive and  risky.26,27
Therefore we decided not to include it in our study.
So, if we intend to maintain bilirubin levels as close as
possible to the physiological values observed in full-term
newborns, early treatment is the recommended choice.28
The hypothesis that the late indication of phototherapy
could substantially reduce the number of treated infants
was not confirmed, as only one newborn in this group did
not have to be treated. The indication of phototherapy for
most children with high levels of bilirubin also was observed
by Curtis-Cohen et al.
The length of treatment of newborns in the early-
treatment group was considerably longer (96 versus 51
hours). These data confirm the results of a previous
study.20 Longer duration of phototherapy obviously implies
in higher exposure of the patients to its side effects.
However, these side effects can be easily overcome.29
As for the costs of both treatments, the prolonged
length of phototherapy does not increase costs incurred
by the length of hospital stay, since newborns weighing
less than 2,000 g usually cannot be discharged before
seven days. The additional cost of phototherapy sessions
(hours) will probably exceed the costs of TB measurements
used for the monitoring of the late-treatment group. In
services where noninvasive measurement of bilirubin
levels is not available, repeated blood collections constitute
a risk of infection, besides the discomfort of the needle
prick for blood collection.
Given the difficulty in establishing the diagnosis of
kernicterus based on specific tests and safe levels of
serum bilirubin and the narrow relationship between high
levels and their persistence, we consider early treatment
with phototherapy to be the best option. After observing
the levels obtained within the first 24 hours in both
groups, there is no reason to start treatment before 24
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hours. The cost and discomfort of prolonged phototherapy
seem to be easily overcome.
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